EFTA00638630Set 9
2016-09-2535p10,821w
computer, using wallpaper patterns and
various landmarks as their guides. Those with preclinical Alzheimer's found it harder to learn the
locations of objects in the maze.
Navigation skill test ... used in this study to assess cognitive map skills was more sensitive at
detecting preclinical Alzheimer's disease than the standard psychometric task of episodic memory,"
says Denise Head, associate ... with learning as well
as voluntary movement. "Our observations suggest a progression such that preclinical Alzheimer's
disease is characterized by hippocampal atrophy and associated cognitive mapping difficulties,
particularly during
https://www.justice.gov/epstein/files/DataSet%209/EFTA00638630.pdf
EFTA01100261Set 9
2016-02-2939p20,086w
universe of available
diseases is large; however, all of these programs are currently in preclinical development and unlikely to move
into the clinic in the near-term. The most advanced ... Catalysts
The key upcoming catalysts for Editas include updates to the interference proceeding, updated preclinical data at
the ASGCT conference in May and an IND filing on its first clinical ... could have an impact on Editas.
Exhibit 6: Editas Catalyst Calendar
Milestones Timing
Updated preclinical data at ASGCT 2016 May 4-7, 2016
Potential new business development 2016
Potential interference
https://www.justice.gov/epstein/files/DataSet%209/EFTA01100261.pdf
EFTA01092032Set 9
25p12,760w
sheep had an identical stromal receptor
found in humans, making the sheep an ideal preclinical model for Mesoblast's MPC product (for human
studies, Mesoblast isolated MPC cells with ... autologous cell safer than the starting material?
That can only be answered in the preclinical and clinical studies. Mesoblast has shown in preclinical and
clinical trials that its cells ... either 20 million ADRCs (n=10) or a placebo (n=4).
There is solid preclinical data showing efficacy of ADRC in myocardial infarction. In a porcine model,
after induction
https://www.justice.gov/epstein/files/DataSet%209/EFTA01092032.pdf
EFTA00857649Set 9
2018-03-164p1,957w
VERU), a biopharmaceutical company
focused on urology and oncology, announced that data from a preclinical study of VERU-111, a novel oral alpha
and beta tubulin inhibitor, showing potent activity ... drug
resistance, myelosuppression and hypersensitivity reactions. Further, this drug has been shown to have
preclinical activity in other cancer types and should have clinical activity in these other cancers ... triple negative breast cancer, ovarian cancer, pancreatic
cancer, lung cancer, and melanoma. In preclinical studies, VERU-111 appears to have less toxicity and less
suppression of white blood cells compared
https://www.justice.gov/epstein/files/DataSet%209/EFTA00857649.pdf
EFTA02714282Set 11
8p3,952w
approval status irrespectively of the clinical trial results. However, based on the results of
preclinical studies on animals where the result was 100% protection from an otherwise
lethal dose ... sensitivity and overcome the limitations of patient compliance.
The Company is expecting to complete preclinical work and file for IND in the second half of
2014, and hope for Phase ... number of research projects that the Company has in early clinical and
preclinical phase. Post the Capital
Competitors
The main direct competitors of Tekmira are listed below, the majority
https://www.justice.gov/epstein/files/DataSet%2011/EFTA02714282.pdf
EFTA00810576Set 9
2018-04-0526p9,385w
most valuable assets in the pipeline
VERU-111 is a novel small molecule in preclinical development for treatment of
MCRPC and other taxane resistant cancers. It is an orally available ... drug as well.
Several advantages of VERU-111, potential for market and indication
expansion
Preclinical studies presented by Veru, showed a few advantages compared to
Docetaxel. Oral administration of VERU ... possibly be used singly and/or in combination.
While it is still in preclinical studies. VERU-111, in our view has a very promising
path ahead if it shows safety
https://www.justice.gov/epstein/files/DataSet%209/EFTA00810576.pdf
EFTA01197764Set 9
8p3,954w
approval status irrespectively of the clinical trial results. However, based on the results of
preclinical studies on animals where the result was 100% protection from an otherwise
lethal dose ... sensitivity and overcome the limitations of patient compliance.
The Company is expecting to complete preclinical work and file for IND in the second half of
2014, and hope for Phase ... number of research projects that the Company has in early clinical and
preclinical phase. Post the Capital
Competitors
The main direct competitors of Tekmira are listed below, the majority
https://www.justice.gov/epstein/files/DataSet%209/EFTA01197764.pdf
EFTA01110707Set 9
22p7,189w
Dates: 12/01/01- 07/31/04
Total Direct Costs: $200,000
Funding Agency: Canavan Fund, NY
Title: Preclinical Studies for Gene Transfer of Canavan Disease
Project Dates: 05/31/99 - 06/01/01
Total Direct Costs ... Canavan (Tremor) Rat Model and in children affected by
Canavan Disease: Targeted Development of Preclinical and Clinical Studies. XIVth International
Workshop on Genetic Systems in the Rat, Kyoto, Japan
https://www.justice.gov/epstein/files/DataSet%209/EFTA01110707.pdf
EFTA02718803Set 11
2015-08-142p301w
yday plans =o scrap a
planned Phase 2b trial and instead initiate added preclinical st=dies to investigate optimal dose, delivery of AVA-101 and
AVA-201in wet age-related ... drawing board," nex= key catalyst may be
decision on therapy in 1H afte= preclinical studies
completed, lefferies analyst B=ren Amin writes; may also
deprioritize its experimenta c=lor blindness
https://www.justice.gov/epstein/files/DataSet%2011/EFTA02718803.pdf
EFTA01206026Set 9
2015-08-143p514w
yday plans to scrap a
planned Phase 2b trial and instead initiate added preclinical studies to investigate optimal dose, delivery of AVA-101 and
AVA-201 in wet age-related ... drawing board," next key catalyst may be
decision on therapy in 1H after preclinical studies
completed, Jefferies analyst Biren Amin writes; may also
deprioritize its experimenta color blindness programs
https://www.justice.gov/epstein/files/DataSet%209/EFTA01206026.pdf
EFTA00848766Set 9
2015-08-143p303w
yday plans to scrap a
planned Phase 2b trial and instead initiate added preclinical studies to investigate optimal dose, delivery of AVA-101 and
AVA-201 in wet age-related ... drawing board," next key catalyst may be
decision on therapy in 1H after preclinical studies
completed, Jefferies analyst Biren Amin writes; may also
deprioritize its experimenta color blindness programs
https://www.justice.gov/epstein/files/DataSet%209/EFTA00848766.pdf
EFTA00669798Set 9
2013-08-273p897w
scored poorly in the absence
of published data. Therefore, at this stage of preclinical development, I am actively seeking the interest
of a creative and daring innovator such as yourself ... support crucial interim funding required to
complete the preclinical proof-of-principle data required for a scholarly publication and future grant
funding.
Last but not least, I would like
https://www.justice.gov/epstein/files/DataSet%209/EFTA00669798.pdf